Tasly Pharmaceutical Group Co Ltd

Tasly Pharmaceutical Group Co Ltd

Health CarePharmaceuticals & Biotechnology
  • Price (CNY)13.49
  • Today's Change0.18 / 1.35%
  • Shares traded8.78m
  • 1 Year change-8.42%
  • Beta0.7049
Data delayed at least 15 minutes, as of Apr 16 2021 08:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • 600535:SHH price moved over -1.05% to 13.25
  • 600535:SHH price rises above 15-day moving average to 13.48 at 15:00 BST

Key statistics

On Friday, Tasly Pharmaceutical Group Co Ltd (600535:SHH) closed at 13.49, 3.13% above its 52-week low of 13.08, set on Feb 03, 2021.
52-week range
13.08Feb 03 202119.97Sep 07 2020
Previous close13.31
Average volume7.44m
Shares outstanding1.51bn
Free float718.71m
P/E (TTM)20.78
Market cap20.13bn CNY
EPS (TTM)0.6406
Annual div (ADY)0.33
Annual div yield (ADY)2.48%
Div ex-dateJun 12 2020
Div pay-dateJun 12 2020
Data delayed at least 15 minutes, as of Apr 16 2021 08:00 BST.
More ▼
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.